Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes?

[1]  R. Pedrinelli,et al.  Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. , 2008, Atherosclerosis.

[2]  Tarl W. Prow,et al.  Nanoparticle-delivered biosensor for reactive oxygen species in diabetes , 2008, Vision Research.

[3]  B. Waeber,et al.  [Stratification of global cardiovascular risk according to the ESH/ESC guidelines]. , 2007, Revue medicale suisse.

[4]  G. Ertl,et al.  Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus. , 2007, Pharmacological research.

[5]  T. Ishimitsu,et al.  Combination Therapy With Telmisartan and Spironolactone Alleviates L-NAME Exacerbated Nephrosclerosis With an Increase in PPAR-γ and Decrease in TGF-β1 , 2007 .

[6]  Michael Adler,et al.  Comment prévenir les complications de la cirrhose , 2007 .

[7]  A. Gressner,et al.  Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options , 2007, Comparative hepatology.

[8]  E. A. Bernard,et al.  Regulation of LPS stimulated ROS production in peritoneal macrophages from alloxan-induced diabetic rats: involvement of high glucose and PPARgamma. , 2007, Life sciences.

[9]  R. Brock,et al.  Obesity, Insulin Resistance and Hepatic Perfusion , 2007, Microcirculation.

[10]  R Weiskirchen,et al.  Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets , 2006, Journal of cellular and molecular medicine.

[11]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[12]  N. Ozaki,et al.  Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. , 2005, Diabetes care.

[13]  T. Kurtz,et al.  Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system , 2004, Journal of hypertension.

[14]  Y. Tokusashi,et al.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis , 2004, Hepatology.

[15]  A. Sampson,et al.  Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: Volume, neuron number, and cell types , 2004, The Journal of comparative neurology.

[16]  Mitchell A. Avery,et al.  Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity , 2004, Hypertension.

[17]  H. Jaeschke,et al.  Chlorotyrosine protein adducts are reliable biomarkers of neutrophil-induced cytotoxicity in vivo , 2004, Comparative hepatology.

[18]  P. B. Lai,et al.  Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response , 2003, Regulatory Peptides.

[19]  R. Marcos,et al.  A New Approach to an Unbiased Estimate of the Hepatic Stellate Cell Index in the Rat Liver: An Example in Healthy Conditions1 , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  H. Aburatani,et al.  Angiotensin II–Induced Insulin Resistance Is Associated With Enhanced Insulin Signaling , 2002, Hypertension.

[21]  P. Arner.  Insulin resistance in type 2 diabetes: role of fatty acids , 2002, Diabetes/metabolism research and reviews.

[22]  H. Saito,et al.  Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. , 2001, Hepatology research : the official journal of the Japan Society of Hepatology.

[23]  S. Kaplan,et al.  A simple technique to measure the movements of the microscope stage along the x and y axes for stereological methods , 2001, Journal of microscopy.

[24]  P. Angus,et al.  Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. , 2001, Journal of hepatology.

[25]  D. Schuppan,et al.  Matrix as a modulator of hepatic fibrogenesis. , 2001, Seminars in liver disease.

[26]  V. P. Chacko,et al.  Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? , 2001, Cancer research.

[27]  P. Leung,et al.  Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. , 2001, Journal of molecular endocrinology.

[28]  M. Fung,et al.  Chronic hypoxia induced down-regulation of angiotensinogen expression in rat epididymis , 2001, Regulatory Peptides.

[29]  P. Leung,et al.  Chronic hypoxia upregulates the expression and function of AT(1) receptor in rat carotid body. , 2000, The Journal of endocrinology.

[30]  K. Catt,et al.  International union of pharmacology. XXIII. The angiotensin II receptors. , 2000, Pharmacological reviews.

[31]  R. Bataller,et al.  Angiotensin II induces contraction and proliferation of human hepatic stellate cells. , 2000, Gastroenterology.

[32]  S. Friedman.  The virtuosity of hepatic stellate cells. , 1999, Gastroenterology.

[33]  K. Cianflone,et al.  Regulation of Plasma fatty acid metabolism. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[34]  H. Gundersen,et al.  The efficiency of systematic sampling in stereology — reconsidered , 1999, Journal of microscopy.

[35]  C. Klein,et al.  Effect of losartan, an Angiotensin II receptor antagonist, on portal pressure in cirrhosis , 1999, Hepatology.

[36]  A. Gressner,et al.  (Latent) transforming growth factor β in liver parenchymal cells, its injury‐dependent release, and paracrine effects on rat hepatic stellate cells , 1998, Hepatology.

[37]  C. Kahn,et al.  Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. , 1997, The Journal of clinical investigation.

[38]  G. Paolisso,et al.  Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients , 1997, Journal of Human Hypertension.

[39]  C. Kahn,et al.  Cross-talk between the insulin and angiotensin signaling systems. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Rockey,et al.  Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance , 1996, Hepatology.

[41]  Jun-Ji Yu,et al.  Fat-storing cells and liver fibrosis , 1996 .

[42]  H. Gundersen,et al.  The isector: a simple and direct method for generating isotropic, uniform random sections from small specimens , 1992 .

[43]  G. Gibbons,et al.  Molecular Mechanisms of Vascular Renin‐Angiotensin System in Myointimal Hyperplasia , 1991, Hypertension.

[44]  T. Mattfeldt,et al.  Estimation of surface area and length with the orientator , 1990, Journal of microscopy.

[45]  H J Gundersen,et al.  The efficiency of systematic sampling in stereology and its prediction * , 1987, Journal of microscopy.

[46]  J. Habener,et al.  Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. , 1986, The Journal of clinical investigation.

[47]  B. Fleshler,et al.  The Liver: Biology and Pathobiology , 1983 .

[48]  V. Arroyo,et al.  Effect of angiotensin‐ll blockade on systemic and hepatic haemodynamics and on the renin‐angiotensin‐aldosterone system in cirrhosis with ascites , 1981, European journal of clinical investigation.

[49]  Greta L. Hoetzer,et al.  Metabolic syndrome and endothelial fibrinolytic capacity in obese adults. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[50]  M. de Gasparo.  Angiotensin II and Nitric Oxide Interaction , 2002, Heart failure reviews.

[51]  R. Ardaillou.  Angiotensin II receptors. , 1999, Journal of the American Society of Nephrology : JASN.

[52]  V. Howard,et al.  Unbiased Stereology: Three-Dimensional Measurement in Microscopy , 1998 .

[53]  Gupta.  Prospects and perspectives of natural plants products in medicine , 1994 .

[54]  D. Campbell,et al.  Circulating and tissue angiotensin systems. , 1987, The Journal of clinical investigation.